Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 788 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hpv Clear all
Completed Phase 2 Interventional Results available

Efficacy and Tolerability of Topical LFX453 for External Genital Warts

NCT02482428
View directory record Official record
Conditions
External Genital Warts
Interventions
Investigational Treatment, Aldara
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Arlington Heights, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Jul 21, 2026, 11:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Increasing Uptake of Evidence-Based Screening Services Through CHW-led Multi-modality Intervention

NCT02970136
View directory record Official record
Conditions
Human Papillomavirus, Human Immunodeficiency Virus, Hepatitis C, ColoRectal Cancer
Interventions
OraQuick Swab, Fecal Immunochemical Test, OraQuick Fingerstick, Standard Screening Tests, HPV Self-Sampling Test, Home Based Screening Tests
Device · Other
Lead sponsor
University of Miami
Other
Eligibility
50 Years to 64 Years
Enrollment
754 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 27, 2021 · Synced Jul 21, 2026, 11:09 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Human Papillomavirus (HPV) Oral Transmission Study in Partners Over Time

NCT01342978
View directory record Official record
Conditions
Oropharyngeal Cancer, Human Papillomavirus
Interventions
Not listed
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older
Enrollment
242 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2017
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Jul 21, 2026, 11:09 AM EDT
Terminated Phase 1 Interventional

Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors

NCT04958434
View directory record Official record
Conditions
Locally Advanced or Metastatic Cancers, Metastatic Human Papillomavirus-Related Malignant Neoplasm
Interventions
TST005
Drug
Lead sponsor
Suzhou Transcenta Therapeutics Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Canton, Ohio • Dallas, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2023 · Synced Jul 21, 2026, 11:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Prospective Evaluation of Self-Testing to Increase Screening

NCT03898167
View directory record Official record
Conditions
Cervical Cancer, Human Papillomavirus Infection
Interventions
Telephone Recall, Mailed HPV Self-Sampling Kit, Patient Navigation
Behavioral
Lead sponsor
Baylor College of Medicine
Other
Eligibility
30 Years to 65 Years · Female only
Enrollment
2,474 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Jul 21, 2026, 11:09 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)

NCT07552558
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, HPV-Negative Squamous Cell Carcinoma
Interventions
Hypofractionated Stereotactic Body Radiotherapy (SBRT), Pembrolizumab, Ficerafusp alfa
Radiation · Biological · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Jul 21, 2026, 11:09 AM EDT
Completed Not applicable Interventional Results available

Use of a Proliferation Saturation Index to Determine Personalized Radiotherapy for HPV + Oropharyngeal Cancers

NCT03656133
View directory record Official record
Conditions
Oropharyngeal Cancer
Interventions
Radiotherapy fractionation
Radiation
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Jul 21, 2026, 11:09 AM EDT
Completed Phase 2 Interventional Results available

Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection

NCT00513526
View directory record Official record
Conditions
Infection, Precancerous Condition
Interventions
Gardasil
Biological
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older · Male only
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Jul 21, 2026, 11:09 AM EDT
Active, not recruiting Phase 2 Interventional

Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT04862650
View directory record Official record
Conditions
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Oral Cavity Squamous Cell Carcinoma, Metastatic Oropharyngeal Squamous Cell Carcinoma, Pathologic Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Squamous Cell Carcinoma of Unknown Primary, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVB Hypopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Lip and Oral Cavity Cancer AJCC v8, Stage IVC Hypopharyngeal Carcinoma AJCC v8, Stage IVC Laryngeal Cancer AJCC v8, Stage IVC Lip and Oral Cavity Cancer AJCC v8
Interventions
Carboplatin, Cemiplimab, Paclitaxel
Drug · Biological
Lead sponsor
Marcelo Bonomi
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jul 21, 2026, 11:09 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 11 and 17

NCT01461993
View directory record Official record
Conditions
Vaccines, Meningococcal Vaccines
Interventions
rLP2086 and Gardasil, rLP2086, Gardasil
Biological
Lead sponsor
Pfizer
Industry
Eligibility
11 Years to 17 Years
Enrollment
2,499 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
87
States / cities
Daphne, Alabama • Chandler, Arizona • Jonesboro, Arkansas + 57 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2018 · Synced Jul 21, 2026, 11:09 AM EDT
Terminated Not applicable Interventional Results available

Self-sampling for Human Papillomavirus (HPV) Among Patients Receiving Colposcopy

NCT04585243
View directory record Official record
Conditions
HPV
Interventions
Evalyn Brush
Device
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
30 Years to 65 Years · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Jul 21, 2026, 11:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

HPV Vaccine Intervention for Young Sexual Minority Men

NCT04032106
View directory record Official record
Conditions
Healthy Subject
Interventions
Best Practice, Informational Intervention, Questionnaire Administration, Text Message-Based Intervention
Other · Behavioral
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years to 25 Years · Male only
Enrollment
1,227 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
2
States / cities
Minneapolis, Minnesota • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Jul 21, 2026, 11:09 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Health Care Decisions for Female Adolescents: The Role of Mothers and Daughters in Decision Making

NCT00807898
View directory record Official record
Conditions
Cervical Cancer
Interventions
Not listed
Lead sponsor
University of Louisville
Other
Eligibility
13 Years and older · Female only
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Jul 21, 2026, 11:09 AM EDT
Active, not recruiting Not applicable Interventional

Provider-Focused Intervention for Maximizing HPV Vaccine Uptake in Young Cancer Survivors

NCT04469569
View directory record Official record
Conditions
Papillomavirus Vaccines
Interventions
HPV-PROTECT
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
9 Years and older
Enrollment
5,196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
6
States / cities
Birmingham, Alabama • Atlanta, Georgia • Minneapolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Jul 21, 2026, 11:09 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-069)

NCT04708041
View directory record Official record
Conditions
Papillomavirus Infections
Interventions
9vHPV vaccine
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
9 Years to 26 Years
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2029
U.S. locations
14
States / cities
Daly City, California • Oakland, California • Roseville, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2025 · Synced Jul 21, 2026, 11:09 AM EDT
Completed Phase 2 Interventional

Study With a Topical Gel to Treat Common Warts in Adults

NCT00117923
View directory record Official record
Conditions
Warts
Interventions
Resiquimod
Drug
Lead sponsor
Graceway Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 18, 2007 · Synced Jul 21, 2026, 11:09 AM EDT
Completed No phase listed Observational

Acceptance of Human Papillomavirus Vaccination in Postpartum Women

NCT00730704
View directory record Official record
Conditions
Human Papilloma Virus, HPV, Post Partum
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 26 Years · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 4, 2012 · Synced Jul 21, 2026, 11:09 AM EDT
Recruiting Phase 2 Interventional

Merck IIT: RRP Pembro and Lenvatinib

NCT04645602
View directory record Official record
Conditions
Human Papilloma Virus, Recurrent Respiratory Papillomatosis, Pulmonary Disease
Interventions
Lenvatinib, Pembrolizumab
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 21, 2026, 11:09 AM EDT
Completed Phase 2 Interventional Results available

Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer

NCT01084083
View directory record Official record
Conditions
Head and Neck Cancer, Precancerous Condition
Interventions
cetuximab, intensity-modulated radiation therapy (IMRT), Paclitaxel, Cisplatin
Biological · Radiation · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
121
States / cities
Birmingham, Alabama • Greenbrae, California • Palo Alto, California + 86 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Jul 21, 2026, 11:09 AM EDT
Completed Phase 1 Interventional

Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection

NCT03239223
View directory record Official record
Conditions
HSIL, HSIL of Cervix, High-Grade Squamous Intraepithelial Lesions, High-grade Cervical Intraepithelial Neoplasia, Human Papilloma Virus, Cervical Cancer, Cervical Intraepithelial Neoplasia, Cervical Neoplasm, Cervical Dysplasia, CIN
Interventions
ABI-1968
Drug
Lead sponsor
Antiva Biosciences
Industry
Eligibility
25 Years to 50 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
6
States / cities
Los Angeles, California • Lake Worth, Florida • Idaho Falls, Idaho + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Jul 21, 2026, 11:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Phase II Evaluation of AHCC for the Eradication of HPV Infections

NCT02405533
View directory record Official record
Conditions
Human Papilloma Virus, Dysplasia, CIN1, CIN2
Interventions
AHCC 3 grams once a day, Placebo
Dietary Supplement · Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
30 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Jul 21, 2026, 11:09 AM EDT
Terminated Phase 2 Interventional Results available

Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma

NCT03799445
View directory record Official record
Conditions
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Basaloid Carcinoma, Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Posterior Tongue Squamous Cell Carcinoma, Soft Palate Squamous Cell Carcinoma, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7, Tonsillar Squamous Cell Carcinoma
Interventions
Intensity-Modulated Radiation Therapy, Ipilimumab, Nivolumab, Quality-of-Life Assessment, Questionnaire Administration
Radiation · Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Jul 21, 2026, 11:09 AM EDT
Recruiting Phase 2 Interventional

A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)

NCT05307939
View directory record Official record
Conditions
HPV, Oropharynx Cancer, HPV-Related Carcinoma, HPV-Related Malignancy, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Interventions
HPV ctDNA Assay, MRI Studies, EORTC QLQ H&N 35 and C30, MDADI-HN, COST-FACIT, Intensity-Modulated Radiation Therapy (Arm A), Chemoradiation (Arm B)
Diagnostic Test · Behavioral · Radiation + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
8
States / cities
Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jul 21, 2026, 11:09 AM EDT
Not yet recruiting Phase 1 Interventional

Use of ACU-D1 in HPV Associated Vulvar and Perianal Lesions in People With HIV

NCT06233331
View directory record Official record
Conditions
Human Papilloma Virus, Human Immunodeficiency Virus, Anal Intraepithelial Neoplasia, High-Grade Squamous Intraepithelial Lesions
Interventions
Dose Level 1 ACU-D1 ointment, Dose Level 2 ACU-D1 ointment, Dose Level 3 ACU-D1 ointment, Vulvar/ Perianal Biopsy
Drug · Procedure
Lead sponsor
Emory University
Other
Eligibility
21 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Jul 21, 2026, 11:09 AM EDT